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Summary
We have analyzed a panel of 14 cases of childhood
adrenocortical tumors unselected for family history and
have identified germline TP53mutations in 180%, mak-
ing this the highest known incidence of a germline mu-
tation in a tumor-suppressor gene in any cancer. The
spectrum of germline TP53 mutations detected is re-
markably limited. Analysis of tumor tissue for loss of
constitutional heterozygosity, with respect to the germ-
line mutant allele and the occurrence of other somatic
TP53 mutations, indicates complex sequences of genetic
events in a number of tumors. None of the families had
cancer histories that conformed to the criteria for Li-
Fraumeni syndrome, but, in some families, we were able
to demonstrate that the mutation had been inherited. In
these families there were gene carriers unaffected in their
40s and 50s, and there were others with relatively late-
onset cancers. These data provide evidence that certain
TP53 alleles confer relatively low penetrance for pre-
disposition to the development of cancer, and they imply
that deleterious TP53 mutations may be more frequent
in the population than has been estimated previously.
Our findings have considerable implications for the clin-
ical management of children with andrenocortical tu-
mors and their parents, in terms of both genetic testing
and the early detection and treatment of tumors.
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Introduction
Childhood adrenocortical tumors are rare, with an in-
cidence of 0.3/million children/year. Adrenocortical car-
cinoma (ACC [MIM 202300]) shows an apparent bi-
modal age distribution, with a median age at onset of
childhood disease of 3 years, and a median age at onset
of adult disease of 55–59 years of age (data based on
information from the Manchester Children’s Tumor
Registry, England, and the Office of National Statistics,
Wales). Childhood ACC is known to occur at a consid-
erably increased frequency in patients with Beckwith-
Wiedemann syndrome (BWS [Wiedemann 1983]), and
in families with Li-Fraumeni syndrome (LFS [Li et al.
1988]). In a high proportion of the latter, the cancer-
prone condition is associated with inheritance of a germ-
line mutation in the TP53 gene (Malkin et al. 1990;
Birch et al. 1994a; Varley et al. 1997a). In families af-
fected by LFS and including childhood ACC, the disease
appears to be highly penetrant, with other carriers of
the germline TP53 mutation presenting with typical LFS
tumors (e.g., bone and soft-tissue sarcomas and breast
and brain tumors) at exceptionally young ages (Birch et
al. 1994a; Varley et al. 1997a). In a series of families
studied by our own group, all of those in which there
was an adrenocortical tumor carried a germline TP53
mutation (Varley et al. 1997a). In spite of strong asso-
ciations between LFS, ACC, and germline TP53 muta-
tions, there has so far been only one study which has
attempted to determine the frequency of germline TP53
mutations in a consecutive series of children with ACC,
and, in that study, three of six patients analyzed were
shown to carry TP53 mutations (Wagner et al. 1994).
There are no reports of germline mutations in sporadic
adult ACCs.
We have obtained material from 14 cases of adreno-
cortical tumors in children aged !15 years, who have
been selected as having no significant family history of
cancer or a family history which did not conform to LFS
or Li-Fraumeni–like syndrome (LFL [Birch et al.
1994a]). We examined the material for the presence of
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germline and somatic TP53 mutations, loss of hetero-
zygosity (LOH), p53 and mismatch-repair protein ex-
pression, and microsatellite instability. The majority of
patients with childhood adrenocortical tumors have
germline TP53 mutations, which can be associated with
a dramatic accumulation of further mutations in the tu-
mors. Although these patients were selected for the ab-
sence of family histories of cancer that are consistent
with LFS/LFL, detailed examination of their family his-
tories identified individuals with tumors and suggested
that the TP53 mutations we have found predispose to
cancer with low penetrance. Thus, germline TP53 mu-
tations may be more frequent than has been estimated
previously.
Patients and Methods
Clinical Samples
Eleven patients were ascertained as a population-
based series of children with adrenocortical tumors
(Manchester Children’s Tumor Registry). From this
same registry, two additional families conforming to the
definition of LFS had been ascertained and studied as
part of a separate cohort (Birch et al. 1994a; Varley et
al. 1997a). Three further patients who had been referred
to our hospital, but resided outside the boundaries of
the Registry’s catchment area, were also included. The
series therefore comprised, in total, 14 cases of adreno-
cortical tumor. Three of the patients had a personal his-
tory of multiple independent primary tumors, all within
the radiation field of the original tumor, and all of types
highly suggestive of a germline TP53 mutation (i.e., soft-
tissue sarcomas and osteosarcomas). The clinical details
of the patients included in this study are given in table
1. The patients’ ages at diagnosis of the adrenocortical
tumors had a range of !1–14 years. Twelve of the tumors
were confirmed as ACC; the remaining two were clas-
sified as adrenocortical adenomas. In both of the latter
cases, the patients are alive as of this writing (December
1998) and well into their 20s. One of these patients
(patient 10) was diagnosed with mild hemihypertrophy,
and his mother was recorded to have a bifid left renal
pelvis and duplication of the ureter in the upper quarter.
The research project had the approval of the local dis-
trict’s medical-research ethics committee.
Sections (10 mm) were cut from fixed, paraffin-em-
bedded tumors, as indicated in table 2. Normal tissue
was obtained from nine patients, either as fixed and
embedded normal tissue, as lymphocytes, or as a lym-
phoblastoid cell line. In addition, normal material was
obtained from the mothers of two affected children who
were first cousins (see below). DNA was extracted ac-
cording to standard protocols (Varley et al. 1997a,
1997b). All tumor sections from which DNA was pre-
pared contained 80% tumor cells, with most com-
prising ∼100%.
Mutation Detection
Exons 2–11 of TP53 were amplified from each sample
(normal and tumor), and the products were screened
initially by SSCP. Included in the analysis were all the
intron-exon boundaries. The primers that were used are
listed in table 3. In each case, a forward (F) and a reverse
(R) primer were used to amplify each entire exon; how-
ever, for some exons, different combinations of primers
also were used (exons 4, 5, and 7). Initially, DNA was
amplified in a first-round standard hot-start PCR of 35
cycles (at 94C, 55C, and 72C, for 1 min each), except
for exon 7, which was amplified using a touchdown
protocol (Don et al. 1991). The products were then di-
luted 1:10 into a second-round SSCP-PCR mix contain-
ing the same reagents as in the first-round PCR, except
with a reduced concentration (10 mM) of unlabeled
dCTP, plus 1 mCi a32P-dCTP per 10-ml reaction (Munn
et al. 1996). The cycling parameters were 10 cycles of
94C, 50C, and 72C, for 1 min each. The products
were separated onto 0.5 # MDE gels (FMC Biochem-
icals) at 4–6 W for 12–16 h, dried, and subjected to
autoradiography as described elsewhere (Munn et al.
1996). Controls (no DNA and normal DNA) were in-
cluded on every gel. Any samples showing abnormal
band shifts were reanalyzed by repeating both first- and
second-round SSCP-PCR reactions. In a number of
cases, the results were verified in an independent labo-
ratory using fresh material.
DNA Sequencing and LOH
The sequence variation that caused the abnormal band
shift was determined by sequencing the product of the
first-round PCR, either with tailed primers or by carrying
out direct sequencing using genomic DNA as a template
and nested tailed PCR primers (Varley et al. 1997a). In
all cases in which both these methods were used identical
mutations were seen, and DNA sequencing was per-
formed in both directions in multiple independent re-
actions to confirm the results. In five cases, a duplicate
blood/DNA sample was analyzed independently in a sec-
ond laboratory, and our results were confirmed. LOH
was determined either from the SSCP gel (i.e., loss of
bands representing the normal allele were compared to
the control on the same gel) or from the sequencing
electropherogram (Varley et al. 1997b).
Where an SSCP band shift or sequencing alteration
was detected (in either normal or tumor material), the
entire experiment was repeated with fresh material. The
results were consistent in every case. Wherever a mu-
tation was detected in normal DNA, the mutant band/
nucleotide appeared to be in the heterozygous state, by
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Table 1
Clinical Details of the Children Included
Patient Number (Sex) Family History (Age at Diagnosis, in Years)a Clinical History (Age at Diagnosis, in Years) XRTb
1 (F) 3d-degree relative, stomach/pancreatic cancer (61);
4th-degree relative, breast cancer (42)
ACC (!2); chondrosarcoma (11);
sclerosing osteosarcoma (12); died (12)
Yes
2 (F) Uncle, NHL rectum (15) ACC (13); died (13) nk
3 (F) Grandmother, cerebral tumor (35) ACC (2); died (4) Yes
4 (F) NFH ACC (!1); spindle-cell sarcoma, breast (14);
died (15)
Yes
5 (F) Mother, lung cancer (58 [smoker]) ACC (!1); osteochondroma (13);
leiomyosarcoma (26); died (27)
Yes
6 (F) NFH ACC (3); died (5) Yes
7 (F) Cousin (patient 8) ACC (4); grandmother, uterine
cancer (57)
ACC (14); died (15) No
8 (F) Cousin (patient 7) ACC diagnosed at 14 years;
grandmother, uterine cancer (57)
ACC (4); died (6); Yes
9 (F) Grandmother, cervical cancer (56); breast cancer
(65)
Adrenocortical adenoma (4); alive (23) No
10 (M) NFH (mild hemihypertrophy) Adrenocortical adenoma (7); alive (25) No
11 (F) NFH ACC (5); alive (17) No
12 (M) Grandfather, astrocytoma (44); 4th-degree rela-
tive, chondosarcoma (35)
ACC (!3); alive (3) nk
13 (F) Grandmother, brain tumor (42) ACC (!2); alive (2) nk
14 (F) Father, glioma (35); grandfather, prostate cancer
(70)
ACC (9); died (10) Yes
a “NFH” denotes no significant family history of cancer and “NHL” denotes non-Hodgkins lymphoma.
b Treatment of the patient with radiotherapy for the primary adrenocortical tumor; “nk” denotes not known.
comparison with known examples of germline TP53
mutations analyzed in parallel. Somatic mutations in tu-
mors were also confirmed by repeating first- and second-
round PCRs and sequencing. We are therefore confident
that PCR artifacts have been excluded.
Immunohistochemistry
Immunohistochemical detection of p53 protein was
performed with the CM1 antibody (Bartek et al. 1991;
Midgley et al. 1992) on sections from fixed and embed-
ded material, as described elsewhere (Birch et al. 1994b).
The extent of the staining was assessed as the percentage
of cells staining and was expressed with respect to the
intensity of staining within those cells (see table 2). Neg-
ative and positive controls were processed at the same
time, and they are the same as those described elsewhere
(Birch et al. 1994b). Expression of the mismatch-repair
proteins MLH1 and MSH2 was performed with com-
mercial antibodies, according to the manufacturer’s in-
structions (PharMingen). Staining was assessed as being
“moderate” or “strong,” as “nuclear or cytoplasmic,”
and, when appropriate, as “negative.”
Mismatch Repair and Microsatellite Analysis
Four mononucleotide tracts (hMSH3, hMSH6,
BAT26, and BAT40 [Parsons et al. 1995; Malkhosyan
et al. 1996]) and four dinucleotide-repeat sequences
(D2S123, D3S1076, D8S255, and D13S175 [Dib et al.
1996]) were analyzed. DNA was amplified in a 10-ml
reaction mix that contained reduced unlabeled dCTP
and 1 mCi 32P-dCTP per reaction. All sequences were
amplified for 35 cycles of 94C, 56C, and 72C each
for 1 min, following an initial 4-min denaturation at
94C. Microsatellites were analyzed by electrophoresis
on a 6% denaturing acrylamide gel and were visualized
by autoradiography.
Results
Germline Mutations in TP53
Germline TP53 mutations were identified in nine cases
(table 2). In addition, although we were unable to obtain
normal DNA from two other patients, analysis of con-
stitutional DNA from cancer-affected relatives identified
germline TP53 defects (shown as inferred mutations in
table 2). Of the remaining three cases, a germline TP53
mutation was excluded by SSCP analysis in two patients,
including one with mild hemihypertrophy. In this latter
case, it is possible that the occurrence of an adreno-
cortical tumor is associated with BWS and thus is more
likely to be linked to a gene or genes on chromosome
11p15 rather than to TP53. In the final case, we were
unable to obtain normal DNA for analysis, although we
detected TP53 mutations in the tumor DNA. However,
it is not possible to determine whether these mutations
represent germline or somatic events. One of the patients
with an adrenocortical adenoma (patient 9) had an in-
Table 2
TP53 Gene Analysis in Childhood Adrenocortical Tumors
PATIENT
NUMBER
GERMLINE
MUTATIONa
TUMOR TYPE
(AGE AT DIAGNOSIS,
IN YEARS)
SOMATIC
MUTATIONb LOHc
p53 EXPRESSION (% OF
CELLS) IN
Tumord Normal Tissues
1 152, ProrLeu, CCGrCTG
inferred
ACC (!2) nt* nt*  (195)  (195)
Chondrosarcoma (11) (152, ProrLeu, CCGrCTG)
Multiple, including
144, GlnrStop, CACrTAG
158, ArgrTyr, CGCrTAC
Intron 6 TrC
SSCP shift exon 7
SSCP shift exon 10
Loss of this allele
LOH
 (195)
Osteosarcoma (12) (152, ProrLeu, CCGrCTG)
152, ProrArg, CCGrCGG
Loss of this allele
LOH
nd
2 No ACC (13) Intron 9 TrA
SSCP shift in exon 5
SSCP shift in exon 7
LOH  (195) / (195)
3 158, ArgrHis, CGCrCAC ACC (2) 158, ArgrHis, CGCrCAC
No other SSCP shift in exons 4–9
LOH nd  (!5)
4 158, ArgrHis, CGCrCAC ACC (!1) 158, ArgrHis, CGCrCAC
No other SSCP shift in exons 2–11
No LOH  (195)  (195)
Sarcoma breast (14) 158, ArgrHis, CGCrCAC
No other SSCP shift in exons 2–11
LOH  (195)
5 152, ProrLeu, CCGrCTG ACC (11) (152, ProrLeu, CCGrCTG)
158, ArgrHis, CGCrCAC
230, ThrrLeu, ACCrATC
248, ArgrGln, CGGrCAG (only exons 4–9 analyzed)
Loss of this allele
LOH
 (195)  (195)
Osteochondroma (13) (152, ProrLeu, CCGrCTG)
130, LeurPhe, CTCrTTC (only exon 5 analyzed)
Loss of this allele
LOH
 (195)
6 na ACC (3) 337, ArgrHis, CGCrCAC
CrT intron 6
CrT intron 10
LOH  (195)  (195)
7 152, ProrLeu, CCGrCTG ACC (14) 152, ProrLeu, CCGrCTG; SSCP shift in exon 7 LOH / (50) nd
8 152, ProrLeu, CCGrCTG ACC (4) 152, ProrLeu, CCGrCTG
240, SerrAsn, AGTrAAT
250, ProrPro, CCCrCCT
LOH
No LOH at 240/250
/ (195) nd
9 152, ProrLeu, CCGrCTG
inferred
AC adenoma (4) (152, ProrLeu, CCGrCTG)
250, ProrPro, CCCrCCT
Loss of this allele
No LOH
/ (195) nd
10 No AC adenoma (7) No SSCP shift exons 2–11 No LOH / (60) / (195)
11 152, ProrLeu, CCGrCTG ACC (5) (152, ProrLeu, CCGrCTG)
176, CysrTyr, TGCrTAC (only exons 4–9 and 11 analyzed)
Loss of this allele
LOH
 (195)  (195)
12 158, ArgrHis, CGCrCAC ACC (!3) 158, ArgrHis, CGCrCAC
No other SSCP shift in exons 2–11
No LOH / (195)  (195)
13 213, ArgrStop, CGArTGA ACC (!2) 213, ArgrStop, CGArTGA
No other SSCP shift in exons 2–11
LOH / (50) nd
14 251, IlerIle, ATCrATT
Homo/Hemizygous
ACC (9) nt* nt*  (195)  (195)
a Germline mutations were identified by screening normal DNA from the patient except in the case of patients 7 and 8, where an identical mutation was found in their
respective tumors, and the mutation was confirmed to be germline by analysis of their mothers’ DNA. In patients 1 and 9, normal material was unavailable from the patients
themselves, but a germline mutation was identified in relatives in the same lineage. The abbreviation “na” denotes normal tissue unavailable for analysis.
b Somatic mutations were identified by screening DNA isolated from the tumor indicated. The notation “*nt” denotes no tumor. In the two cases indicated, no tumor material
was available. In some cases, SSCP shifts were seen, but sequencing to characterize the precise mutation was not performed. In cases where there is a germline mutation, the
details given in this column are for additional mutations in the tumor.
c LOH was assessed from either the SSCP gel or from the sequencing electropherogram as loss of one allele.
d p53 expression was assessed as weak (), moderate (), or strong (), and the percentage of cells showing such staining are given. Normal tissues evaluated include
normal adrenal gland, adjacent tissues, or normal material from distant sites.
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Table 3
PCR Primers Used for SSCP Analysis of TP53
EXON
PRIMERS
PCR CONDITIONSaForward Reverse
2 2F1 (5′-AAGCGTCTCATGCTGGATCCC-3′) 2R (5′-GCCCTTCCAATGGATCCACT-3′) Standard  10% DMSO
3 3F (5′-GAAGCGAAAATTCATGGGACTGA-3′) 3R1 (5′-CCCCAGCCCAACCCTTGTC-3′) Standard  10% DMSO
4A 4F (5′-GACCTGGTCCTCTGACTGCTC-3′) 4R2 (5′-TGCAGGGGCCGCCGGTGTAG-3′) Standard  10% DMSO
4B 4F2 (5′-CTACACCGGCGGCCCCTGCA-3′) 4R (5′-GCATTGAAGTCTCATGGAAG-3′) Standard
5 5F (5′-ATCTGTTCACTTGTGCCCTG-3′) 5R (5′-ATCAGTGAGGAATCAGAGGC-3′) Standard
5A 5F (5′-ATCTGTTCACTTGTGCCCTG-3′) 5R2 (5′-CTCACAACCTCCGTCATGTG-3′) Standard (1.5mM MgCl2)
5B 5F2 (5′-TTGCCAACTGGCCAAGACCT-3′) 5R (5′-ATCAGTGAGGAATCAGAGGC-3′) Standard
6 6F (5′-GCCTCTGATTCCTCACTGAT-3′) 6R (5′-GGAGGGCCACTGACAACCA-3′) Standard (1.5mM MgCl2)
7 7F (5′-CTTGCCACAGGTCTCCCCAA-3′) 7R (5′-AGGGGTCAGCGGCAAGCAGA-3′) Touchdown (Don et al. 1991)
7A 7F (5′-CTTGCCACAGGTCTCCCCAA-3′) 7R2 (5′-TGATGATGGTGAGGATGGGCC-3′) Standard  10% DMSO
7B 7F2 (5′-ATCTCCTAGGTTGGCTCTGAC-3′) 7R (5′-AGGGGTCAGCGGCAAGCAGA-3′) Standard  10% DMSO
8 8F (5′-TTCCTTACTGCCTCTTGCTT-3′) 8R (5′-TGAATCTGAGGCATAACTGC-3′) Standard
9 9F (5′-GCAGTTATGCCTCAGATTCA-3′) 9R (5′-ACTTTCCACTTGATAAGAGG-3′) Standard
10 10F (5′-CCATCTTTTAACTCAGGTAC-3′) 10R (5′-TATGGCTTTCCAACCTAGGAA-3′) Standard
11 11F (5′-CTCACTCATGTGATGTCATC-3′) 11R (5′-CAAAATGGCAGGGGAGG-3′) Standard
a Standard PCR conditions were as follows (final concentrations): 1 # Taq buffer (Promega Corporation), 200 mM each dNTP, 1.0 mM
MgCl2, 0.25 mM each primer, 0.2 units Taq polymerase (Promega). Some reactions as indicated were performed using an increased concentration
of MgCl, or with the addition of DMSO. Amplification of exon 7 was performed using a touchdown protocol. Further details of cycling
parameters are given in the text.
ferred mutation (see table 2). We have previously re-
ported that benign lesions occur in germline TP53 mu-
tation carriers and that, indeed, there can be loss of the
wild-type allele in such lesions (Varley et al. 1996).
The spectrum of mutations detected is remarkable.
Among patients with a confirmed or inferred germline
TP53 mutation, six had identical mutations at codon
152 (ProrLeu, CCGrCTG), and three had identical mu-
tations at codon 158 (ArgrHis, CGCrCAC). Apart
from two affected first cousins (see table 1 andtable 2),
as far as we have been able to determine from a very
detailed pedigree analysis, none of the patients are re-
lated. One other patient (patient 13) was found to have
a nonsense mutation at position 213. Identical germline
mutations have been reported previously at this position
in patients with LFS (Frebourg et al. 1995) and in pa-
tients with a strong family history of cancer (Horio et
al. 1994). In the remaining case with a germline muta-
tion, we identified a silent mutation at codon 251, which
is homo- or hemizygous. There are no reports of this
nucleotide change in the TP53 database (Beroud and
Soussi 1998), and the substitution is not predicted to
alter splicing or mRNA stability. One explanation for
this finding is that one allele of TP53 has the codon 251
substitution, whereas the other has a deletion of all or
part of the gene. We have not been able to study this
finding further, because of the limited availability of ma-
terial from this patient.
Family History
Although all the cases in this report were selected be-
cause they were not members of families that conformed
to the definitions of LFS/LFL, nonetheless, a number did
have suspicious family histories (table 1). Two of the
patients were first cousins, affected with ACC at ages 4
years and 14 years (patients 7 and 8). The mothers of
these children are unaffected at ages 47 years and 42
years, respectively, although both have been shown to
carry the germline TP53 mutation. The maternal grand-
mother developed carcinoma of the uterus at age 57
years and also carried the identical mutation (with no
LOH in the tumor). In three other cases in which we
have detected a germline mutation, although all parents
are unaffected (at ages 51 years), one grandparent in
each family developed a brain tumor in their 30s or 40s.
We have not been able to obtain material from these
brain tumors to analyze the mutation status. Further-
more, in one of these families, a second cousin developed
a chondrosarcoma in his 30s. In one other family in
which a germline mutation was detected, the father of
a 9-year-old child with ACC developed a brain tumor
in his mid-30s. The mother of patient 5 developed a lung
adenocarcinoma at age 58 years. Although this is not
an unusually young age for a smoker to develop such a
tumor, she was shown to carry the identical germline
mutation to that of her daughter.
In families 1 and 9, although we were unable to an-
alyze normal DNA from the proband, we were able to
obtain archival normal material from affected relatives.
In neither family was the history of cancer particularly
striking, with respect either to the ages at onset or to
the tumor types. However, in both families, we were able
to detect a germline mutation in the normal DNA from
affected relatives.
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Figure 1 Diagrammatic interpretation of the somatic changes
in tumors from patients 5 (a) and 8 (b).
Somatic Mutations and LOH
In all cases except two, we were able to examine the
adrenocortical tumor DNA for somatic TP53 mutations
and LOH. The simplest model of action for a tumor-
suppressor gene is that one mutation (usually missense
or nonsense) is inherited and the remaining allele either
is lost by some deletion mechanism or suffers a second
mutational hit (Ponder 1988). Thus, one might expect
that in an adrenocortical tumor of a patient with an
inherited germline TP53 gene, there will be either loss
of the wild-type allele or a second mutational event. The
situation in some of the tumors examined in the present
study is far from being so simple.
Among the four tumors examined from three patients
with a codon 158 mutation (patients 3, 4, and 12), there
is LOH in two of the tumors and no LOH in the other
two, with no additional SSCP band shifts in any tumor.
In earlier studies, we (Varley et al. 1997b) and others
(Sedlacek et al. 1998) have shown that there is LOH in
about half of all tumors from patients with germline
TP53 mutations, so this finding is not unusual. However,
it is somewhat surprising that we have not detected a
second mutation in the two tumors in which there is no
LOH. In the tumor from the patient with a germline
codon 213 nonsense mutation, there is LOH.
In all the tumors of patients with a germline codon
152 mutation, there are multiple additional somatic mu-
tations. In three tumors there is loss of the confirmed
germline mutant allele (patient 5, ACC and osteochon-
droma; patient 11, ACC), and in three other tumors
there is loss of the inferred germline mutant allele (pa-
tient 1, chondrosarcoma and osteosarcoma; patient 9,
adrenocortical adenoma). In our previous study of LOH
in tumors, we found two cases in which there was loss
of the germline mutant allele in tumors, one of which
was an ACC (Varley et al. 1997b). In all tumors with
codon 152 mutations, there are additional missense mu-
tations within both the exons and the flanking intronic
sequences (table 2). In some of the tumors, the situation
is extremely complex, with both loss of the inherited
mutant allele and multiple additional somatic mutations.
There are some intriguing findings in both tumors from
patient 5, most strikingly in the ACC. Analysis of exons
4–9 from this tumor show that there are three somatic
mutations, affecting codons 158, 230, and 248 (table
2). None of these mutations are present in the consti-
tutional DNA isolated from a lymphoblastoid cell line
from this patient, and all of them are present in the
homozygous/hemizygous state in the tumor. One expla-
nation for this finding is that there have been a number
of mutational events affecting the normal germline allele
of TP53, including the classic hot-spot codon 248 mu-
tation. There has subsequently been loss of the inherited
mutant copy of TP53, possibly as a result of selective
pressure imposed by the presence of one of the other
candidate tumor-suppressor genes on chromosome 17
(see fig. 1a). Perhaps the most interesting aspects of this
finding of multiple mutational hits in the adrenocortical
tumor are the young age at onset (!1 year) and the
number of missense mutations within a single gene. It
is tempting to speculate that either there has been some
exposure to DNA-damaging agents in utero, or that
there has been a somatic mutation in a second gene
whose product is involved in the maintenance of ge-
nomic stability. In two patients with an inferred germline
codon 152 mutation (patients 1 and 9), we have ob-
served similar findings to the above, namely loss of the
inherited mutant allele and further somatic mutations,
all showing LOH.
In the ACC from patient 8, there is LOH at position
152 (the germline mutation), with loss of the wild-type
sequence at this position, but there are two somatic mu-
tations within exon 7, at positions 240 and 250, which
are present in the heterozygous state. The latter mutation
is silent (CCCrCCT, ProrPro). The simplest explana-
tion for this finding is that the wild-type chromosome
is lost and the mutant chromosome reduplicated, with
subsequent mutational hits occurring in one allele (fig.
1b). Although this model suggests that both mutations
occur in the same allele, we cannot rule out the possi-
bility that they occur on different alleles. Interestingly,
we also detected a codon 250 CCCrCCT change in
DNA from another adrenocortical tumor (patient 9).
This change has not been previously reported as a poly-
morphism, and we have never seen this change in any
control or cancer-affected individual ( , data notn 1 100
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shown), although there is one report of an identical
change in a squamous carcinoma of skin (Campbell et
al. 1993). The significance of this silent alteration is un-
clear, but it might again be a consequence of increased
genomic instability.
In one further patient (patient 6), mutations were ob-
served in the tumor, with complete loss of the wild-type
allele. We were unable to determine whether these mu-
tations were inherited or acquired. Finally, in one of the
two cases (patient 2) in which we have been unable to
find a germline TP53 mutation, we have detected mul-
tiple somatic TP53 mutations.
Detection of p53 by Immunohistochemistry
We were able to stain all the adrenocortical tumors
except one (see table 2) for the expression of p53 protein.
In addition, normal tissues were stained from the ma-
jority of patients and, wherever possible, from other pri-
mary tumors (see table 2). The extent of staining was
assessed using two criteria: the percentage of cells stain-
ing, and the intensity of staining in the positive cells. In
all cases examined, there was detectable p53 staining.
In most tumors, there was staining in the majority of
tumor cells, with a moderate-to-strong intensity indi-
cating increased stabilization of the protein, relative to
the normal wild-type state. Interestingly, in all cases in
which we were able to examine normal tissue, the stain-
ing was at least as strong as in the tumors, and, in some
cases, even more intense (see table 2). In two cases in
which we were unable to analyze normal DNA for germ-
line TP53 mutations, there was detectable staining for
p53 protein in normal cells.
Expression of MSH2 and MLH1
Twelve adrenocortical tumors (patients 1–12) were
studied for the expression of MLH1 and MSH2 by im-
munostaining. Adrenocortical tumors from two patients
(patients 5 and 7) showed loss of expression of both
proteins, and two others (patients 2 and 4) showed com-
plete loss of expression of MLH1 but not of MSH2.
Cytoplasmic staining of MLH1 was apparent in two
tumors (from patients 1 and 11). The remaining six tu-
mors showed nuclear expression of both proteins, al-
though in no case were all the tumor cells stained with
both antibodies. It would appear, therefore, that a sig-
nificant proportion of the childhood adrenocortical tu-
mors studied have compromised mismatch repair. There
is no correlation between the position of the TP53 mu-
tation and loss of expression of the mismatch repair
genes.
Microsatellite Instability
We looked for evidence of microsatellite instability
(MI) in the tumors by means of both mononucleotide
and dinucleotide repeats. Only one tumor from a patient
with a codon 152 mutation (patient 1, chondrosarcoma)
showed evidence of MI, but because of the limited avail-
ability of normal material for comparison and difficulties
amplifying some repeats from several of the other sam-
ples, we cannot draw any firm conclusions about the
occurrence of MI in the adrenocortical tumors.
Discussion
Of 14 patients analyzed in this study, we have been
able to obtain normal DNA from 11, 9 (82%) of whom
have confirmed TP53 germline mutations. Two of the
remaining three patients have inferred germline muta-
tions. This is a remarkably high frequency of germline
mutation and represents the highest incidence of a germ-
line mutation reported in any cancer. Since we have used
SSCP as a primary screen for TP53 mutations, the figure
may be an underestimate. The spectrum of mutations
found in childhood adrenocortical tumors in the present
study is extremely interesting. All the patients with germ-
line mutations except two have alterations to codons
152 or 158 (table 2). There is one other report in the
literature of a germline mutation in codon 152, intri-
guingly in the only other published study of children
with ACC (Wagner et al. 1994). There are no reports
of a germline codon 158 mutation. These two residues
lie within the core DNA-binding domain of the TP53
gene, but are outside the highly conserved domains. Both
are, however, conserved in all species examined to date
(Soussi et al. 1990), strongly indicating that they have
an essential role in the function of the normal p53 pro-
tein. We have analyzed fibroblasts from an unaffected
individual with a germline codon 152 mutation, and
have demonstrated that the cells show reduced transient
G1 arrest and an increased cell survival following irra-
diation and that the mutant p53 fails to transactivate in
a yeast functional assay (Boyle et al. 1999). These data
confirm that the mutant protein is functionally
abnormal.
This is only the second study to examine the frequency
of germline TP53 mutations in childhood adrenocortical
tumors. The patients were unselected for any family his-
tory and cases consistent with LFS/LFL were excluded,
which may explain the limited spectrum of mutations
detected. There are numerous other reports of germline
TP53 mutations in families in which there is a child with
an adrenocortical tumor, many of which conform to the
definitions of classic LFS or LFL (Sameshima et al. 1992;
Bardeesy et al. 1994; Birch et al. 1994a; Hamelin et al.
1994; Stolzenberg et al. 1994; Strauss et al. 1995; Varley
et al. 1997a; Sedlacek et al. 1998; Vital et al. 1998). In
addition, there are a number of reports of children with
adrenocortical tumors who either have some family his-
tory of cancer (Grayson et al. 1994; Pivnick et al. 1998)
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or no family history of cancer at all, some of which
represent de novo mutations (Gutierrez et al. 1994; Wag-
ner et al. 1994; Giunta et al. 1996; Moutou et al. 1996).
Finally, there are some reports of individuals with germ-
line mutations and adult-onset adrenocortical tumors
(Warneford et al. 1992; Felix et al. 1993; Lubbe et al.
1995; Varley et al. 1998). The spectrum of germline
mutations seen in the above studies is broad, in contrast
to the narrow range in this present report. However, in
the majority of the above reports, there was a strong
family history of cancer associated with the ACC cases,
and three other cases carried de novo mutations. The
present series was population-based but did not include
those cases meeting the LFS/LFL criteria, and this could
explain the limited spectrum of mutations observed. It
is noteworthy that in the only other series of ACC that
was unselected for family history one of the three germ-
line TP53 mutations detected was at codon 152 (Wagner
et al. 1994). It seems unlikely that there is a population
difference, because, in LFS/LFL studied in our laboratory
in which there is a case of childhood ACC, we see a
variety of mutations, including missense mutations at
codons 220, 248, 180, and 175, a complex deletion-
insertion event, and a splicing mutation (Birch et al.
1994a; Varley et al. 1995; Varley et al. 1997a).
A number of the patients with germline TP53 muta-
tions have relatives with tumors characteristic of LFS,
although the clustering of cancers in those families does
not fulfill the clinical criteria for classic LFS or for LFL.
In one family, first cousins were affected with ACC at
ages 4 years and 14 years, and, although their mothers
are unaffected at ages 42 years and 47 years, they both
carry the mutant allele. In addition, in this same family,
a second-degree relative of the probands is an germline
carrier unaffected at age 45 years. In the report by Wag-
ner et al. (1994), the mother of a child with an ACC
and an identical germline codon 152 mutation, although
unaffected at the time of the study, developed breast
cancer at age 46 years. Four other children in the present
study have a first- or second-degree relative affected with
a brain tumor at age !45 years, with obligate carriers
unaffected at ages up to the mid-60s. These data, there-
fore, suggest that there exists a subset of germline TP53
mutations that are of lower penetrance than those de-
tected in families that conform to the definitions of LFS
or LFL. This hypothesis is strengthened by the finding
that in two families, although normal material from the
probands with the adrenocortical tumors was unavail-
able, analysis of an affected relative revealed the exis-
tence of a germline mutation, and in both families there
were unaffected relatives who are inferred obligate
carriers.
The current estimates for lifetime penetrance in in-
dividuals with a germline TP53 mutation approach 90%
(LeBihan et al. 1995), and analysis of first primary can-
cers in 20 families affected by LFS or LFL that contain
germline TP53 mutations showed that mean age at di-
agnosis was 28 years (Birch and Varley, unpublished
data). These data apparently would place the unaffected
carriers in the families reported here at very high risk.
However, these risk estimates of TP53 germline muta-
tion carriers are based on the analysis of a relatively
small number of families ascertained according to the
clinical definitions of LFS or LFL. There could, therefore,
be a considerable bias in these risk estimates. In the series
of families in the present study, the ascertainment has
been made to exclude families with clinical LFS or LFL,
but otherwise without regard to family history, and it
was based solely on the occurrence of a case of childhood
adrenocortical cancer. Apart from the index case, there
are no additional cases of childhood cancer, and the ages
at onset of the brain and breast tumors in these families
appears to be later than in those with classic LFS who
carry a germline mutation affecting a known mutational
hotspot (Birch et al. 1998). Finally, a number of relatives
of children with adrenocortical tumors who have been
shown to carry germline mutations have developed tu-
mors that are not normally associated with LFS, includ-
ing lung, uterine, and cervical tumors. These data all
support the proposal that the mutations we have de-
tected, predominantly in codons 152 and 158 of TP53,
are of relatively low penetrance, both in terms of the
incidence of cancer and in terms of the tumor types.
Low-penetrance alleles have been identified in other
cancer-predisposition syndromes, most notably retino-
blastoma (Onadim et al. 1992; Dryja et al. 1993; Loh-
mann et al. 1994; Bremner et al. 1997; Schubert et al.
1997; Cowell and Bia 1998). The spectrum of mutations
seen in such families is distinctly different from that seen
in patients with severe phenotypes or in families showing
high penetrance (Cowell and Bia 1998; Harbour 1998).
The mutations that we have detected at high frequency
in patients with childhood adrenocortical tumors and
with no or mild family histories of cancer do not, at first
sight, appear to be of a different class than those seen
in higher penetrance LFS/LFL families. Further biolog-
ical studies are in progress to address this important
point and to determine the consequences of the codon
152 and 158 mutations.
The findings reported here have considerable impli-
cations for patients with childhood adrenocortical tu-
mors and their families. Genetic screening should be con-
sidered, and, if a mutation is found, it might be
appropriate to offer carriers screening for breast and
brain tumors using protocols which minimize exposure
to ionizing radiation (e.g., magnetic resonance imaging
or ultrasound). Three of the children who were treated
with radiotherapy survived 12 years, and all three de-
veloped additional primary tumors within the radiation
field (table 1). None had received chemotherapy. These
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secondary tumors were typical of those seen in carriers
of germline TP53 mutations: bone and soft-tissue sar-
comas. There are other reports in the literature of ther-
apy-induced secondary tumors in germline TP53 mu-
tation carriers (Felix et al. 1996, 1998; Hisada et al.
1998), but those reported in the present study are par-
ticularly striking.
We performed very detailed analysis of TP53 for LOH
in the tumors and for the occurrence of second muta-
tions. These data proved extremely interesting. In the
tumors from patients with a codon 158 or 213 mutation,
there are few other alterations, limited to loss of the wild-
type allele. In contrast, tumors from patients with codon
152 mutations showed an unusually high number of
somatic mutations. The selective drive for the accumu-
lation of such mutations is not apparent and may reflect
an increased genomic instability as a result of the specific
mutation. This is a testable hypothesis and, if verified,
would be the first demonstration of a TP53 muta-
tion–specific function in the recognition or accumulation
of DNA damage. We tested a number of the tumors for
expression of the mismatch-repair genes MLH1 and
MSH2, to determine whether the high incidence of so-
matic missense mutations in tumors from patients with
codon 152 mutations reflected a generalized defect in
mismatch repair, possibly as a direct consequence of the
germline mutation. Although mismatch repair appears
to be compromised in a number of tumors, there is no
correlation with the type of TP53 mutation. If specific
mutations do lead to an increased genomic instability as
proposed above, it does not manifest as an increase in
chromosomal gain and loss as judged by CGH (James
et al. 1999).
Of the 17 somatic mutations that we have character-
ized, 14 involve either CrT or GrA transitions. Of these
14, 6 occur at CpG dinucleotides (see table 2). Spon-
taneous deamination of cytosine residues at either CpG
or meCpG is considered to be the most significant source
of transition mutations of the type seen in the tumors
reported in the present study. Since there are specific
DNA glycosylases which recognize the U:G and T:G mis-
matches generated by deamination of CpG or meCpG,
respectively, the increase in mutations may be associated
with defects in these pathways, or, perhaps, a signifi-
cantly increased spontaneous deamination rate could ac-
count for the observations reported here. Studies of com-
ponents of excision repair pathways are underway, in
order to shed light on these intriguing observations.
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